How to buy Altimmune stock - 24 Feb price $17.2 |

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Altimmune stock | $17.2

Own Altimmune stock in just a few minutes.


Fact checked

Altimmune, Inc is a biotechnology business based in the US. Altimmune shares (ALT) are listed on the NASDAQ and all prices are listed in US Dollars. Altimmune employs 43 staff and has a trailing 12-month revenue of around USD$8.2 million.

How to buy shares in Altimmune

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Altimmune. Find the stock by name or ticker symbol: ALT. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Altimmune reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$17.2, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Altimmune, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Altimmune. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Altimmune share price

Use our graph to track the performance of ALT stocks over time.

Altimmune shares at a glance

Information last updated 2021-03-02.
Latest market closeUSD$17.2
52-week rangeUSD$2.5 - USD$35.1
50-day moving average USD$17.4667
200-day moving average USD$14.2814
Wall St. target priceUSD$41.83
PE ratio 1.8247
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-4.161

Buy Altimmune shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stocks, Options, ETFs
Get two free stock valued between $2.50 and $250
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Interactive Brokers
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Altimmune stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Altimmune price performance over time

Historical closes compared with the close of $17.2 from 2021-02-25

1 week (2021-03-01) 4.81%
1 month (2021-02-08) -10.23%
3 months (2020-12-08) 29.91%
6 months (2020-09-08) 35.97%
1 year (2020-03-06) 352.63%
2 years (2019-03-08) 497.22%
3 years (2018-03-08) 929.94%
5 years (2016-03-08) 2.99%

Is Altimmune under- or over-valued?

Valuing Altimmune stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Altimmune's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Altimmune's P/E ratio

Altimmune's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Altimmune shares trade at around 2x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Altimmune financials

Revenue TTM USD$8.2 million
Gross profit TTM USD$8.2 million
Return on assets TTM -16.1%
Return on equity TTM -36.14%
Profit margin 0%
Book value $6.109
Market capitalisation USD$585.5 million

TTM: trailing 12 months

Shorting Altimmune shares

There are currently 2.5 million Altimmune shares held short by investors – that's known as Altimmune's "short interest". This figure is 3.3% down from 2.6 million last month.

There are a few different ways that this level of interest in shorting Altimmune shares can be evaluated.

Altimmune's "short interest ratio" (SIR)

Altimmune's "short interest ratio" (SIR) is the quantity of Altimmune shares currently shorted divided by the average quantity of Altimmune shares traded daily (recently around 1.9 million). Altimmune's SIR currently stands at 1.35. In other words for every 100,000 Altimmune shares traded daily on the market, roughly 1350 shares are currently held short.

However Altimmune's short interest can also be evaluated against the total number of Altimmune shares, or, against the total number of tradable Altimmune shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Altimmune's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Altimmune shares in existence, roughly 70 shares are currently held short) or 0.0782% of the tradable shares (for every 100,000 tradable Altimmune shares, roughly 78 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Altimmune.

Find out more about how you can short Altimmune stock.

Altimmune share dividends

We're not expecting Altimmune to pay a dividend over the next 12 months.

Have Altimmune's shares ever split?

Altimmune's shares were split on a 1:30 basis on 14 September 2018. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Altimmune shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Altimmune shares which in turn could have impacted Altimmune's share price.

Altimmune share price volatility

Over the last 12 months, Altimmune's shares have ranged in value from as little as $2.5 up to $35.1. A popular way to gauge a stock's volatility is its "beta".

ALT.US volatility(beta: 1.36)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Altimmune's is 1.3632. This would suggest that Altimmune's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Altimmune overview

Altimmune, Inc., a clinical stage biopharmaceutical company, focused developing treatments for liver disease, immune modulating therapies, and vaccines. The company develops HepTcell, an immunotherapeutic product candidate that has completed Phase I clinical trial for patients chronically infected with the hepatitis B virus; NasoShield, an anthrax vaccine to provide for protection after a single intranasal administration; NasoVAX, a recombinant intranasal vaccine product candidate; and AdCOVID, a single-dose intranasal vaccine to protect against COVID-19 Its preclinical stage products include ALT-801, a novel peptide-based dual GLP-1/Glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis; and ALT-702, an investigational tumor immunostimulant for treating cancer. The company also develops veterinary product candidates. It has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site